Molecular Landscape of Classical Hodgkin Lymphoma: From Genetic Lesions to Biologically Defined Subtypes
4 affiliations
- 1Laboratory of Experimental Hematology, Institute of Oncology Research, 6500 Bellinzona, Switzerland
- 2Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
- 3Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
- 4Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China
Abstract
Hodgkin lymphoma (HL) represents a unique lymphoid malignancy characterized by the presence of rare malignant Hodgkin and Reed–Sternberg (HRS) cells embedded within a highly complex and immunologically active tumor microenvironment. Over the past decade, advances in genomic and transcriptomic technologies have substantially refined the understanding of HL pathogenesis. Recurrent genetic alterations affecting key oncogenic pathways, including NF-κB, JAK/STAT, and PI3K/AKT signaling, cooperate with widespread mechanisms of immune evasion to sustain tumor cell survival and proliferation. Epstein–Barr virus infection contributes to lymphomagenesis in a significant subset of cases by providing surrogate survival signals, modulating immune interactions and targeting the telomere-shelterin complex through LMP1. In parallel, emerging evidence highlights the central role of the tumor microenvironment, which actively supports malignant cell growth through direct cellular interactions, cytokine signaling, and metabolic and immune-regulatory mechanisms. Recent studies using circulating tumor DNA (ctDNA) profiling and single-cell approaches have enabled non-invasive genomic characterization and revealed biologically distinct molecular subgroups, further underscoring the interplay between tumor genetics and immune contexture. These insights are reshaping disease classification and opening new avenues for biomarker-driven therapeutic strategies. A deeper integration of molecular, immunological, and microenvironmental features will be crucial to optimize risk stratification and to develop more precise and less toxic treatments for patients with HL.
Related
- Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel Molecular Subtypes
- Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1.
- On closing the gap: anti-PD-1-based salvage in relapsed/ refractory classical Hodgkin lymphoma. Comment on: “Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
- The gap narrows but shifts. Response to Comment on: “Mind the gap: anti–PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
- The Comparative Prognostic Value of the Interim PET Deauville Score and ΔSUVmax in Classical Hodgkin Lymphoma: A Real-World Study of Imaging and Inflammatory Markers
BibTeX
@article{pirosa2026molecular,
title = {{Molecular Landscape of Classical Hodgkin Lymphoma: From Genetic Lesions to Biologically Defined Subtypes}},
author = {Maria Cristina Pirosa and Zhihua Yao and Davide Rossi},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203256},
url = {https://www.mdpi.com/2072-6694/18/20/3256},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular Landscape of Classical Hodgkin Lymphoma: From Genetic Lesions to Biologically Defined Subtypes
AU - Maria Cristina Pirosa
AU - Zhihua Yao
AU - Davide Rossi
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203256
UR - https://www.mdpi.com/2072-6694/18/20/3256
AB - Hodgkin lymphoma (HL) represents a unique lymphoid malignancy characterized by the presence of rare malignant Hodgkin and Reed–Sternberg (HRS) cells embedded within a highly complex and immunologically active tumor microenvironment. Over the past decade, advances in genomic and transcriptomic technologies have substantially refined the understanding of HL pathogenesis. Recurrent genetic alterations affecting key oncogenic pathways, including NF-κB, JAK/STAT, and PI3K/AKT signaling, cooperate with widespread mechanisms of immune evasion to sustain tumor cell survival and proliferation. Epstein–Barr virus infection contributes to lymphomagenesis in a significant subset of cases by providing surrogate survival signals, modulating immune interactions and targeting the telomere-shelterin complex through LMP1. In parallel, emerging evidence highlights the central role of the tumor microenvironment, which actively supports malignant cell growth through direct cellular interactions, cytokine signaling, and metabolic and immune-regulatory mechanisms. Recent studies using circulating tumor DNA (ctDNA) profiling and single-cell approaches have enabled non-invasive genomic characterization and revealed biologically distinct molecular subgroups, further underscoring the interplay between tumor genetics and immune contexture. These insights are reshaping disease classification and opening new avenues for biomarker-driven therapeutic strategies. A deeper integration of molecular, immunological, and microenvironmental features will be crucial to optimize risk stratification and to develop more precise and less toxic treatments for patients with HL.
SN - 2072-6694
ER -